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 INTRODUCTION
Disease associated membranoproliferative glomeru-
lonephritis (MPGN) has been well -known for decades. 
Recently, advances in the understanding of the comple-
ment system have shown its direct influence on MPGN-
-related conditions and conditions related to other mor-
phologic entities. The key aspect is the clear demonstration 
of complement component C3 (C3) by immunofluores-
cence (IF) in glomeruli. A new group of rare diseases 
mediated by complement and called C3 glomerulopa-
thies has emerged as part of renal conditions.
How to deal with a glomerulonephritis with predomi-
nant C3 deposits on immunofluorescence?
The answer to this question is now much clearer as 
glomerulonephritis pathogenesis, histology and clinical 
aspects are better defined.
These complex entities are nowadays easier to under-
stand, using a systematic approach and taking into account:
–  the background knowledge of these diseases
–  a better understanding of the complement role in 
this context
–  a systematic way to diagnosis
–  the choice of an appropriate treatment
–  the perception of the evolution of these diseases 
after transplantation
 BACKGROUND
Going back to the 70’s, MPGN classification was 
based on histological and electron microscopy (EM) 
findings1. Clinically they were classified as primary or 
secondary, depending on whether the aetiology was 
known or not. Primary or idiopathic diseases were sub-
divided into type I with mesangial and endocapillar 
proliferation accompanied by mesangial and suben-
dothelial deposits creating double contours; type II 
where intramembranous dense deposits were the hall-
mark with variable proliferation and sometimes double 
contours, and type III similar to type I but with deposits 
in the subendothelial and subepithelial space.
Renée Habib’s group at Necker hospital, a group with 
an extensive experience in children’s biopsies worked 
to develop an improved immunofluorescence tech-
nique, achieving a very good differentiation of the pat-
terns of immunoglobulin and C3 complement factor 
on glomeruli and tubular basement membranes of the 
biopsy specimen. C3 was dominant in type II MPGN 
with dense and linear deposits along the capillary walls 
and also with round deposits over the mesangium with-
out the presence of immunoglobulin. EM revealed the 
dense deposit along the basement membrane and so 
the name of dense deposit disease (DDD) was intro-
duced2. DDD is part of the small and very rare group 
of diseases known today as C3 glomerulopathies.
The presence of immunoglobulin was the main fluores-
cence evidence in type I MPGN with little complement.
Low levels of serum complement were a well -known 
phenomenon although its role in the pathogenesis of 
these entities was largely unknown.
By 2011, immunofluorescence microscopy acquired 
a central role in the understanding of the MPGN patho-
genesis. A very special focus on composition and com-
bination of the deposits in the glomeruli determined 
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a new classification based on the quality of deposits 
seen by IF3,4. MPGN type I shows deposits of immu-
noglobulin IgG/IgM/IgA and small amounts of comple-
ment C3. Diversely, MPGN DDD only shows deposits 
of C3, with small or no immunoglobulin deposits. Type 
III may show both deposits.
A more sophisticated interpretation of MPGN made 
by IF, by Vivette D’Agaty et al. was published in 2014, 
comprising 319 cases of primary MPGN type I -III, rep-
resenting a new look at MPGN5. The presence of immu-
noglobulin corresponds to type I/type III MPGN, and 
C3 alone is associated with MPGN type II. In this IF study 
the expression C3 dominant in the context of C3 glo-
merulopathy was proposed, as C3 is much more intense 
than any other deposit. These criteria imply investiga-
tion of the alternative complement pathway.
As in the past, pathologists diagnose dense MPGN 
deposits by EM and C3 IF deposits. Nevertheless, strong 
evidence showed that in an important number of cases 
the membranoproliferative aspects seen by light 
microscopy (LM) were absent, and definitely the des-
ignation of dense deposit disease - DDD - prevailed over 
MPGN type II.
While restricted C3 deposits were described by 
pathologists in MPGN type I and III, different morpho-
logical aspects by LM could be seen. The glomeruli could 
be almost normal, show mesangial or endocapillar 
glomerulonephritis and even show crescents. These 
GN with dominant C3 deposits and variable LM aspects 
are called C3 glomerulonephritis. This designation 
encompasses GN with different aspects by LM but with 
C3 and with no or small intensity immunoglobulin.
Prevailing C3 deposits in glomeruli are the basis of 
the electron -dense deposits image seen on EM. In some 
cases, these deposits show a very dense osmiophilic 
image which was given the name of DDD, whereas in 
other cases the deposits do not show this appearance 
and are designated C3 glomerulonephritis (C3GN). The 
distinction is not always clear -cut and an overlap of 
morphological and pathogenic aspects may occur.
 COMPLEMENT
It is now established that complement regulation 
plays a central role in disorder pathogenesis such as 
MPGN and haemolytic uraemic syndrome (HUS). Its 
functional complexity is due to more than 30 proteins 
either circulating in plasma or in cell membranes. Com-
plement activity depends of three pathways that rule 
our innate and acquired immunity. Those pathways act 
via C3 convertase on C3, giving origin to fragment C3a, 
an anaphylatoxin, and C3b, a potent opsonin. Rapid 
amplification of C3b can generate millions of C3b mol-
ecules within minutes. C3b with C3 originate C5 con-
vertase which cleaves C5 in C5a and C5b. C5b triggers 
the terminal complement cascade, including C5b, C6, 
C7, C8, and C9 known as membrane attack complex 
(MAC). MAC a porelike, lipophilic protein complex, with 
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Figure 1
Classification of C3 -related Glomerular Diseases
Category Defining Features Complement abnormalities
C3 glomerulopathies
Dense deposit disease (DDD) Extremely dense GBM and mesangial deposits by EM; vari-
able histologic patterns: MPGN, AGN, esangial proliferative, 
crescentic; C3 dominant
Autoantibody to C3bBb or C3; mutation in CHF(rare), 
C3(rare), CFHR1(rare)
C3 glomerulonephritis (primary GN 
with isolated C3)
C3 in mesangium/GBM with deposits less dense than in 
DDD; may have IG but much less intense than C3. Patterns 
MPGN I or III
Autoantibody to C3bBb; mutation in CFH, CFI, MCP,
(all rare)
 CFHR5 nephropathy MPGN type III pattern, autosomal dominant Mutation in CHFR5
 Atypical acute glomerulonephritis Persistent haematuria/proteinuria, with or without history 
of infection; endocapillar and mesangial proliferation and 
subepithelial C3 greater than Ig
Autoantibody to C3bBb 70%; mutation in CFH5 or CFH5R 
30%.
Idiopathic MPGN with Immune Complex Deposition
MPGN type I Proliferation and sub endothelial and mesangial deposits, 
double contours; C3 deposition with Ig and/or C1q
Autoantibody to C3bBb; CFH mutation; CFI mutation; many 
times with classical pathway activation (low C4).
MPGN type III Mesangial proliferation, subepithelial and intramembranous 
deposits; C3 with Ig and/or C1q
Sparse genetic autoimmune data
Adapted from Colvin/Chang. Diagnostic pathology, Kidney Diseases. 2 edition. Elsevier, 2014.
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C5b to C9 that inserts in cell membrane and results in 
cell lysis, Fig 2.
Presence of immunoglobulin and complement in a 
biopsy signals an immune -complex lesion, meaning that 
the classical pathway has been activated by an infec-
tious, autoimmune, malignant associated disease as 
gammopathy. On the contrary, when the immunofluo-
rescence pattern shows deposition of C3 alone, denotes 
that C3 has been activated in tissues by deregulation 
of the alternative pathway Fig.3. This pathway is con-
stantly being produced in an slow manner (“tickover”), 
producing C3 and C3b that with complement factor B 
(CFB) produce fluid convertase C3bBb. Regulation of 
alternative pathway is permanently under the scope 
of multiple proteins in the fluid phase and tissues, 
including complement factors H (CFH) and I (CFI) and 
membrane cofactor protein (MCP).
Any alteration of these proteins breaks the control 
of this pathway transforming its low grade activity into 
a hyperactive phase.
This transformation is the base of C3 glome rulopathies.
By 2012 these glomerulopathies had become indi-
vidualized entities with a better known pathogenesis, 
morphology and clinical features. As in other circum-
stances, many doubts and differences persisted con-
cerning the classification, diagnosis and how and when 
to treat them.
That same year a meeting, took place at Cambridge, 
UK where experts worked to obtain a consensus over 
these entities, on matters such as definition, systema-
tization of complement investigations, and complement 
therapeutics6.
Most of the final conclusions were already known, 
but discussion and exchange of experiences from 
around the world, produced a better understanding 
and clarified the place of C3 glomerulopathies as part 
of glomerulonephritis.
Main conclusions of the 2012 consensus included 
definition, role of complement, therapeutics and 
behaviour after transplantation.
Definition of C3 glomerulopathies was already con-
sensual. They constitute a new category of comple-
ment mediated diseases, with an unequivocal presence 
of glomerular C3 deposits, with little or no immuno-
globulin or electron dense deposits present in 
glomeruli.
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Figure 2
Adapted from Colvin/Chang. Diagnostic pathology, Kidney Diseases. 2 edition. Elsevier, 2014.
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Another important remark is that this denomination 
encompasses a range of conditions independent of LM 
or EM findings.
Attention to complement activity is a focal point; C3 
glomerulopathy and haemolytic uraemic syndrome 
(HUS) are diseases where the activation of an alterna-
tive pathway is the pathogenesis core of both entities. 
They share some alterations but they are different 
diseases.
In HUS complement activation occurs in vascular 
endothelium causing thrombotic microangiopathy and 
there are no glomerular deposits by EM or by IF. C3 is 
absent.
In C3 glomerulopathy, the activation of alternative 
pathway leads to C3 fragmentation with deposition in 
glomeruli without deposits of C1q or C4 or immuno-
globulin. In a few cases we can see small amounts of 
immunoglobulin.
Morphology is further clarified and may present 
many different aspects by LM and by EM. Morpho-
logical features may depict mesangial proliferative 
GN, MPGN, proliferative endocapillar GN. All these 
may show crescents. Rarely glomeruli are normal by 
LM.
EM demonstrates deposits intensely osmiophilic and 
dense, along the glomerular basement membrane, 
identifying DDD. C3 glomerulopathies whose deposits 
do not have the same characteristics of DDD, namely 
density, are designated C3 glomerulonephritis.
Immunochemistry (IHC) or IF that allow demonstra-
tion of intense C3 deposits in the glomeruli of all C3 
glomerulopathies are most outstanding in diagnosis.
When C5b -9 is present in the kidney, revealed by 
IHC/IF, this can be a marker of activation of alternative 
pathway and anti C5 therapy should be considered. 
Nevertheless, presence of C5b -9 complex may occur 
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Figure 3
Illustrative case: MPGN I with immune complex Ig dominant (IgG), negative for C3. (Monoclonal gammopathy of renal significance).
IgG
Illustrative case: DDD with exclusive C3 deposit, negative for immunoglobulin and with dense deposit () by EM (C3 glomerulopathy).
C3
(Cases from Nephrology Service of Curry Cabral Hospital-CHLC)
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in a normal kidney or many months after therapy, even 
when C5 is already normal in serum.
Proteins that make up the complement work in a 
coordinated way under strict control. Some alterations 
(acquired, hereditary or immunologic) of these proteins 
detected by serologic assays provide important infor-
mation about the state of alternative pathway and give 
important diagnostic guidelines:
–  Activation – reduced C3, normal C4, reduced factor B
–  C3 turnover – C3 reduced, C3d augmented
–  C5 turnover – C5 reduced, C5b -9 augmented
–  Measurement of C3 nephritic factors
–  Measurement of serum factor H - Is the major fluid-
-phase regulator of the alternative pathway
–  Serum paraprotein detection – paraprotein may 
be the cause of uncontrolled activation
–  Screening for CFHR5 – this mutation is a cause of 
C3 glomerulopathy.
Issues that must be considered in cases of special 
clinical and serological interpretation requiring a more 
refined interpretation are:
–  Measurement of serum factor B – reduced (Factor 
B circulates in the blood; important in the forma-
tion of C3 convertase)
–  Measurement of serum C5 – reduced in terminal 
pathway activation with some benefit from thera-
peutic C5 inhibition.
–  Measurements of anti factor B autoantibody.
–  Mutation screening of complement regulatory 
genes (CFH, CFB, CFI, and CD46 – membrane com-
plement regulator that exist as multiple isoforms 
in a single cell type).
Recommendations for serological investigation, in 
all patients include:
–  C3, C4, factor H levels, paraproteins,C3Neff
–  Screening for CFHR5
–  Other investigations case by case.
Conclusions of the consensus were published on 2013.
C3 glomerulopathies including DDD and C3GN share 
some morphological, genetic and clinical features. The 
main differences between pathologic and genetic 
aspects were listed above.
Both entities also share clinical aspects. These are 
better known in DDD. C3 glomerulopathy without dense 
deposits, a recently discovered condition with distinct 
identity, represents a heterogeneous group in terms 
of pathogenesis and clinical course.
DDD has a poor prognosis. It is a disease of children 
and young adults. In a series from Nasr, 20087, 39% of 
the adults were over 60 years of age. Males and females 
are affected equally, although some studies show some 
female predominance. The clinical picture is similar to 
that in immune complex MPGN Type I. Almost all 
patients have proteinuria and haematuria. Nephrotic 
syndrome is present from 12% to 65% in different series 
from Nasr and Servais. Renal insufficiency is common 
at presentation and more common in adults. Hyperten-
sion may be seen at onset or in the course of the 
disease.
A minority of patients with DDD may present lipo-
dystrophy, with low levels of serum C3 and positive 
C3NeF. Recently LU et al. described an association 
between DDD and type 1 diabetes mellitus that is not 
yet well clarified8.
For C3GN Servais9 states that mean age at diagnosis 
was 30 years, much higher than for DDD. 25% of 
patients were less than 16 years old. 27% of patients 
had nephrotic syndrome at presentation, compared 
with 38% with DDD and 65% with MPGN type I. Two 
thirds of the patients with C3GN had micro haematuria 
at the beginning of the disease. Significantly at pres-
entation, 40% of C3GN had low C3 compared with 86% 
of low C3 in DDD.
There is a variable outcome according to the under-
lying aetiology. In the French series of Servais9 the mean 
time to ESRD was similar to MPGN and DDD with an 
overall 10 years’ survival of 63%.
80% of men progress to chronic renal failure and 
only 21% of women do. This difference is not yet justi-
fied or understood.
CFHR5 nephropathy is a familial form of C3 GN occur-
ring in patients of Cypriot descent, with CFHR5 muta-
tion10. The major clinical feature is microscopic hae-
maturia in 90% of young patients. Proteinuria appears 
later in older age and 75% that attain ESRF are male.
What can be done when a biopsy with dominant C3 
in the glomeruli occur?
–  First make sure that C3 is clearly dominant over 
the other immune reactants.
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–  Determine with certainty its localization: mesan-
gial, over basement membrane or both, endocapil-
lar, epimembranous.
–  Integrate the IF aspects with the features of LM, 
EM, serological data and clinic.
–  Elaborate a differential diagnosis between MPGN 
and post -infectious GN.
–  EM must reveal the deposits. DDD shows dense 
deposits over the BM and in mesangium. C3GN 
presents less dense deposits in other localizations, 
mesangial, endothelial or epimembranous.
–  If needed check for auto - antibodies and mutations.
  THERAPEUTIC ASPECTS IN C3 
GLOMERULOPATHY
C3 glomerulopathies have not an optimal treatment. 
They are rare, there are no prospective randomized 
clinical trials and aetiopathogenesis was partially under-
stood recently.
In the majority of patients DDD treatment is not 
evidence -based11.
Treatment includes corticosteroids, other immuno-
suppressant, antithrombolitics, anticoagulants and 
plasmapheresis.
Some series12 observed some benefits via a combi-
nation of immunosuppression and rennin -angiotensin 
blockage.
C3 in glomeruli may activate C5 and MAC C5b -9. 
Inhibition of C5 level could ameliorate glomeruli injury 
in DDD. Eculizumab is a humanized antibody with high 
affinity to C5, blocking activation of C5a and C5b and 
subsequently the MAC complex.
In a study by Bomback et al13 six adults with C3 
glomerulopathy were treated with Eculizumab.
After 12 months of therapy, 2 patients with DDD 
showed a significantly reduction in creatinine and 
another patient had reduced proteinuria.
One patient with C3GN showed reduction in creati-
nine and improvement in morphology.
MAC serum levels normalized and repeated biopsies 
showed less inflammation, according with a diminished 
synthesis of the chemotactic C5a.
The pattern of immunofluorescence for C3 and C5b -9 
persisted.
Whom to treat. And what treatment? Does morphol-
ogy predict a response to therapy? Do DDD and C3GN 
respond the same way?
Is therapy against complement unique? Are other 
anti -cellular immunosuppressive therapies of use 
against C3NeF and other antibodies? How long should 
the treatment be maintained?
Future therapy will point to other proteins in comple-
ment cascade, namely to C3 convertase inhibition, impair-
ing C3 breakdown and its deposition in basement mem-
branes and mesangium. Other proteins deserving attention 
are C5 or constituents of terminal complement.
 TRANSPLANTATION
Recurrence of C3 glomerulopathy data is scarce. In 
patients with DDD recurrence is almost universal11.
C3GN recurrence in a recent study with 10 patients 
was 60%9. One case of CFHR5 recurrence has been 
described by Vernon. Recurrence occurred 46 days after 
transplantation14.
One C3GN case, of our own experience, recurred 3 
months after transplantation (unpublished).
Servais’ paper signals that some patients with C3GN 
may develop thrombotic microangiopathy post trans-
plantation7.
 CONCLUSION
Nowadays C3 glomerulopathies are an individualized 
group of diseases with a better defined place in the 
spectrum of glomerulonephritis. Morphologic definition 
of C3 glomerulopathies is concise and based on an 
unequivocal demonstration of C3 in glomeruli. Diagnosis 
begins with that evidence and completes with the dem-
onstration of dense deposits on EM, knowing that LM 
may be diverse. EM permits a sub -division in DDD and 
C3 GN according to deposit density and localization.
The dominant revelation of C3 in glomeruli implies an 
immediate effort to exclude other diseases with dominant 
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C3 in glomeruli, namely post infectious glomerulonephri-
tis. Simultaneously a systematized study of the alternative 
complement cascade must be performed, checking the 
serum alterations of complement factors, the develop-
ment of antibodies against complement proteins and the 
existence of mutations. Following this path we can reach 
a diagnosis and initiate an appropriate treatment, choos-
ing among the options currently available, taking into 
account the best scientific literature.
Eculizumab is a potent anti C5 inhibitor, with an effec-
tive effect in certain cases of C3 glomerulopathies
Other therapies against fulcral proteins in the com-
plement cascade, namely C3 convertase and terminal 
complement are being studied. Antiproliferative ther-
apy with immunosuppression should be considered in 
cases bearing clear demonstration of antibodies against 
complement proteins.
Transplantation data are scarce but recurrence is 
high and the few reported cases seem to point to early 
recurrences.
Finally it must be recognized that our understanding 
of the role of the complement system in glomerular 
lesions are still in its infancy. For instance it is well 
known that C3b receptor (CR1, CD35) is present on the 
surface of normal podocytes, but its function and the 
importance of such presence remains to be defined. 
However recent data suggests that it may protect podo-
cytes from complement mediated injury15.
It is recognized that the access to complement assays requires refer-
ral to specialized laboratories. Taking this point into account we list 
laboratories offering some or all of the complement assays.
−  In Lisboa: Serviço de patologia Clínica – Secção de Imunologia do 
Hospital de S.José – CHLC, tel. 218841875. All serologic measure-
ments of complement factors including factors B, H, I.
−  In Coimbra: Serviço de Hematologia Clínica, Unidade de Hemostase 
do Hospital Pediátrico de Coimbra – CHUC tel: 339488700 Extensão 
– 13901. Antibodies against complement fact ors, mutations of 
complement factors and regulators.
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